WuXi AppTec Reports Record Year-to-Date Results in 2022, Thi

/PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable...

Related Keywords

Shanghai , China , United States , Wuxi , Jiangsu , Hong Kong , Changzhou , Singapore , Middletown , Delaware , Lingang , Jiangxi , Wuhan , Hubei , America , Asia Pacific , International Financial Reporting Standards , Stock Exchange Of Hong Kong , Owners Of The Company , Shanghai Stock Exchange , Third Quarterly Report Of The Company , Manufacturing Organization , Contract Research , National Medical Products Administration , Site Management Organization , Accounting Standard For Business Enterprises , Profit Attributable , Earnings Per Share , Quarterly Report , Stock Exchange , Contract Testing , Reporting Period , Wuxi Chemistry , Changzhou Phase , Wuxi Testing , Wuxi Apptec Investigational New Drug , From January , Wuxi Biology , Shanghai Lingang , Tetracycline Enabled Self Silencing Adenovirus , Licensing Agreement , Trial Applications , Proposed Issuance , Wuxi Apptec , Financial Position , North America , Accounting Standard , Business Enterprises , Health Care Amp Hospitals , Medical Pharmaceuticals , Biotechnology , Banking Amp Financial Services , Earnings ,